Zim Laboratories Ltd. · NSE:ZIMLAB
Zim Laboratories — Q3 FY2022 Earnings Presentation
14 slides from Zim Laboratories's earnings presentation, March 2022
Slide 1: ZIM Laboratories Limited Corporate Presentation - March 2022
ZIM LABORATORIES Limited CORPORATE Presentation - March 2022 01
Slide 2: Disclaimer and Safe Harbor
Disclaimer and Safe Harbor The presentation has been prepared by ZIM Laboratories Limited (“ZIM” or the “Company”) solely for information purposes and does not constitute an offer to sell or recommendation or solicitation of an offer to subscribe for or purchase any securities and nothing contained
Slide 3: Highlights: Q3FY22 and 9MFY22
Highlights: Q3FY22 and 9MFY22 • Total Income for Q3FY22 was Rs.867 Mn (up 13% QoQ and 16% YoY) • Our Core Revenue, which comprises of Pre-Formulation Intermediaries (PFI) exports, Finished Formulation (FF) exports, Oral Thin Films (OTF) and high margin Government of India (GOI) domestic business, gr
Slide 4: Revenue
Revenue • Growth in Core Revenue and its Total Income (Rs. Mn) Total Income (Rs. Mn) increasing contribution to Total Income has been on back of our continued 867 3,061 766 2,790 effort on growing business of higher 649 2,282 margin value added products, primarily for exports • Our lower margin “Non
Slide 5: Highlights: Q3FY22 and 9MFY22 Revenue
Highlights: Q3FY22 and 9MFY22 • Our Exports grew to Rs.726 Mn in Q3 – up from Rs.623 Mn in Q2 (17% growth QoQ); Contribution of Exports to Total Income increased to 84% (Vs 81% in Q1 and Q2 FY22) • Total Exports for 9MFY22 was Rs.1,873 Mn, 10.5% higher than Rs.1,694 Mn for 9MFY21; Contribution of Ex
Slide 6: Exports
Exports Export Revenue (Rs. Mn) • Our exports are primarily to RoW markets of Asia Pacific, 726 Middle East and Africa (MENA), CIS Countries and Latin 623 America Countries (LATAM) 523 • During 9MFY22, we have tied up with 6 companies for marketing of our 5 new products in the Developed Markets Q1 F
Slide 7: Exports
Exports PFI Export (Rs. Mn) PFI Exports (Rs. Mn) • For Q3, FF and PFI exports grew 34% and 13% QoQ resp 498 1,567 442 1,319 1,302 363 • For 9MFY22, the growth in FF and PFI exports was 15% and 13% compared to 9MFY21 resp Q1 FY 22 Q2 FY 22 Q3 FY 22 FY 20 FY 21 9MFY22 • 234 Finished Formulations are r
Slide 8: Oral Thin Films (OTF)
Oral Thin Films (OTF) • During 9MFY22, we received registration and marketing authorization of our Oral Thin Film product - Rizatriptan Benzoate for the EU market (1st product for EU) • Along with Rizatriptan, Tadalafil, Sildenafil, Melatonin, Ondansetron, Vitamin D3, Methylcobalamin, Levocetirizine
Slide 9: Financials: Borrowings
Financials: Borrowings Total Borrowings (Rs. Mn) • During Q3, some of the high-cost NBFC debt were 899 repaid through lower cost Bank borrowings resulting in overall lower debt outstanding and saving in 811 interest expenses 770 • Outstanding debt in December 2021 was at Rs.770 FY 20 FY 21 9MFY22 Mn
Slide 10: Financials: Margins
Financials: Margins • Net Margin % for Q3FY22 expanded to 41.4% compared to 40.7% for Q3FY21 (QoQ). Similarly, Net Margin % for 9MFY22 grew to average 42% (Vs 38.5% in 9MFY21) • Though Operating Expenses have grown on back of growth in business, EBITDA Margin % has seen expansion over the quarters.
Slide 11: Financials: Q3 and 9MFY22
Financials: Q3 and 9MFY22 Key Financial Highlights: Income Statement Particulars (Rs. Mn) Q3FY 22 Q3FY21 Change % (YoY) 9M YTD Dec 21 9M YTD Dec 20 Change % (YoY) Revenue from Operations 860 742 16% 2,254 2,305 -2% Other Income 7 8 -8% 29 16 79% Total Income 867 750 16% 2,282 2,321 -2% Net Margin 36
Slide 12: Research and Development (R&D)
Research and Development (R&D) • Our combined expenses on R&D has been between 6% to 7% R&D Expenses (Rs. Mn) and as % of Total Income (RHS) 250 of Total Income. Of this, around 2/3RD has been in revenue expenses incurred on salary, materials, consumables etc. and 7.0% 6.5% 6.5% the balance on capit
Slide 13: Q3 Shareholding
Q3 Shareholding Overall Shareholding : % • Promoter Group shareholding is free of any Promoter Group 33.26% encumbrance Public • During the period 9M YTD Dec 2021, our private equity 66.74% investor - AA Development Capital Fund 1, LLC (PE Investor) exited the company through secondary sale of its s
Slide 14: Thank You
THANKYOU